Reaction

Metastases To Peritoneum reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,472 reports · 85 co-occurring drugs

As of the last recalculation, Metastases To Peritoneum appears in 2,472 FAERS reports alongside 85 co-occurring drug terms. The strongest observed disproportionality signal is REGORAFENIB (PRR 40.0).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Regorafenib	54	40.0	40.2
Fulvestrant	146	39.5	39.7
Panitumumab	65	35.9	36.0
Olaparib	82	34.1	34.2
Gemcitabine	144	32.6	32.7
Oxaliplatin	235	29.4	29.5
Exemestane	71	28.7	28.8
Gemcitabine Hydrochloride	168	28.5	28.6
Letrozole Tablets	153	28.5	28.6
Letrozole	191	28.2	28.3
Goserelin	44	28.1	28.2
Everolimus Tablets	54	27.7	27.8
Irinotecan Hydrochloride	40	26.6	26.7
Capecitabine	247	25.1	25.2
Bevacizumab	306	23.6	23.7
Paclitaxel (Aibumin-Bound)	205	22.8	22.9
Sorafenib	55	22.8	22.8
Temozolomide	54	22.0	22.1
Paclitaxel	233	21.8	21.8
Fluorouracil Cream, 0.5%	171	20.2	20.2
Everolimus	116	20.1	20.1
Fluorouracil	172	20.0	20.1
Ribociclib	73	20.0	20.1
Dabrafenib	48	19.5	19.6
Trametinib	54	19.2	19.3
Imatinib	38	18.4	18.4
Niraparib	43	16.6	16.6
Leucovorin Calcium	36	16.1	16.1
Ifosfamide	40	15.9	15.9
Sitagliptin And Metformin Hydrochloride	40	15.9	15.9
Pazopanib Hydrochloride	48	15.2	15.2
Erlotinib	16	14.0	14.0
Carboplatin	190	13.6	13.6
Octreotide Acetate	48	13.4	13.5
Cisplatin	119	13.4	13.4
Docetaxel Anhydrous	100	13.0	13.0
Docetaxel	100	13.0	13.0
Erlotinib Hydrochloride	18	12.2	12.2
Doxorubicin Hydrochloride	45	11.8	11.8
Sitagliptin	83	10.0	10.0
Granisetron Hydrochloride	12	9.7	9.7
Alpelisib	10	9.7	9.7
Durvalumab	23	9.6	9.6
Gefitinib	10	9.4	9.4
Imatinib Mesylate	30	9.2	9.2
Vemurafenib	13	9.1	9.2
Cetuximab	33	9.0	9.0
Doxorubicin	90	8.8	8.8
Zoledronic Acid	41	8.7	8.7
Anastrozole Tablets	22	8.7	8.7
Polatuzumab Vedotin	9	7.8	7.8
Pemetrexed	19	7.5	7.5
Dronabinol	7	7.3	7.4
Prochlorperazine Maleate	8	7.3	7.3
Granisetron	9	7.2	7.3
Anastrozole	31	7.2	7.2
Exenatide	43	7.0	7.0
Pemetrexed Disodium	31	6.9	6.9
Axicabtagene Ciloleucel	8	6.8	6.8
Abemaciclib	16	6.8	6.8
Fam-Trastuzumab Deruxtecan-Nxki	8	6.7	6.7
Etoposide	57	6.7	6.7
Dexamethasone Sodium Phosphate	8	6.6	6.7
Trifluridine And Tipiracil	8	6.3	6.3
Encorafenib	7	6.0	6.0
Palbociclib	64	5.8	5.8
Bendamustine Hcl	10	5.4	5.5
Lanreotide Acetate	5	5.4	5.4
Nivolumab	60	5.3	5.3
Osimertinib	20	5.3	5.3
Baricitinib	6	5.3	5.3
Loperamide Hydrochloride Oral	6	5.0	5.0
Lapatinib	9	4.9	4.9
Rucaparib	5	4.8	4.8
Trastuzumab	38	4.7	4.7
Denosumab	96	4.1	4.1
Bleomycin Sulfate	5	4.1	4.1
Atezolizumab	18	3.9	3.9
Cabozantinib	21	3.7	3.7
Pembrolizumab	40	3.2	3.2
Ipilimumab	16	3.1	3.1
Sevoflurane	3	3.0	3.0
Liraglutide	17	2.9	2.9
Methoxy Polyethylene Glycol-Epoetin Beta	3	2.3	2.3
Aflibercept	7	1.9	1.9

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.